West-Ward sees shortages as 'major opportunity'

Citing stats from the FDA on growing drug shortages, Michael Raya of service provider West-Ward is taking action. "We see this as a major opportunity," he says in a statement. The Hikma Pharmaceuticals subsidiary recently acquired Baxter's multi-source injectables business, including a sterile injectable facility. Injectables are among the most common of drugs in short supply. Raya says he envisions West-Ward--with its operations versatility, solid compliance record and network of U.S. and European facilities--as "one of the leading global providers of contract dosage form development and manufacturing services." Release

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.